Table 2.

Cytogenetic response to lenalidomide

Chromosomal abnormality (n)≥50% Decrease in abnormal cells in metaphase, n (%)Complete cytogenetic response, n (%)
Del 5q31.1 (n = 12)10 (83%)9 (75%)
    Isolated (n = 11)98
    With trisomy 21 (n = 1)11
Del (20)(q11.2) (n = 2)00
t(1;22)q(21p11.2) (n = 1)11
Other* (n = 5)00
Total (n = 20)11 (55%)10 (50%)
  • NOTE: Reprinted with permission from List et al. (46). Copyright © 2001 Massachusetts Medical Society. All rights reserved.

  • * Other = +19, t(3;3)(q21;q26.3), +8, −X, and complex karyotypes.